INTRODUCTION
Rare diseases are defined as conditions having an impact on fewer than 200 000 patients annually in the United States, yet approximately 7000 such rare diseases exist and affect millions of people in the United States and countless more worldwide. 1 A 2010 Institute of Medicine report on accelerating research and development for rare diseases and orphan products (i.e., compounds developed for use in rare disease) identified publicprivate collaboration as a key element for accelerated research and product development for these rare diseases; 1 meanwhile, a growing number of regulatory incentives promise to make commercialization of drugs for rare diseases financially plausible.
By their nature, many rare and pediatric cancers frequently have pathognomic genetic abnormalities underlying their pathophysiology, raising the hope that these diseases may be particularly responsive to emerging targeted drug therapies that address these pathognomic changes. The purpose of this review is to demonstrate that childhood rhabdomyosarcoma (RMS) is an excellent proof-ofconcept rare disease from which to show efficacy of a new targeted agent and with which to seek an initial Food and Drug Administration (FDA) approval for commercialization. RMS is the most common childhood soft tissue sarcoma, and the number of cases has conservatively been estimated at 250-350 children per year in North America. 2, 3 New assessments suggest the number of cases may be significantly higher. 4 The incidence is similar in the United States and Europe. [4] [5] [6] Because of the expression of myogenic markers, RMS has historically been thought to arise from muscle. At the time of diagnosis, RMS is clinically characterized as intermediate or high risk in 68% of cases, 7 being metastatic (high risk) in 16% of cases. Most pediatric RMS falls into one of two biologically distinct subgroups: alveolar RMS (aRMS) or embryonal RMS (eRMS), which are defined by histology, 2 and upon which treatments are stratified. aRMS is an extremely aggressive soft tissue tumor with a survival rate of o20% when metastatic. 8, 9 aRMS is characterized by a frequent t(2;13) chromosomal translocation, which creates the PAX3:FOXO1A fusion oncogene, or alternatively a t(1;13) translocation forming the PAX7:FOXO1A oncogene. 2 Fusion gene status strongly associates with outcome 10 and is expected to become a treatment stratifier after prospective clinical trial validation. eRMS does not have a pathognomonic genetic abnormality, yet loss of heterozygosity of 11p15.5, p53 pathway disruption and RAS activation are frequently found in somatic tumors. 2, 3, 11, 12 In fact, it was studies of familial eRMS that led to the initial description of LiFraumeni syndrome over 40 years ago. 13 eRMS is also associated with a better prognosis. Nevertheless, metastatic eRMS portends only 40% overall survival, despite multidisciplinary therapeutic approaches that include surgical resection, irradiation and intensive multi-agent chemotherapy. 8 A wide variety of cytogenetic abnormalities (particularly translocations) and molecular pathways have been implicated in the pathogenesis of sarcomas in general, and significant progress has been made in the past decade toward identifying potential therapeutic targets based on these biomarkers of disease. An obvious next series of steps is to explore new therapeutic approaches using molecular-targeted drug therapies. Fortunately, rare cancers such as pediatric RMS are receiving new attention from the pharmaceutical industry as proof-of-concept diseases for which a rare cancer with a specific disease mechanism can be investigated and understood through preclinical and clinical trial validation studies, thereby leading to an initial FDA approval for a new compound. From this point, the successful compound can be expanded to related diseases in a 'one pathway-many diseases' paradigm.
14 How far a proof-of-concept can be generalized might depend upon the importance of the mechanism in driving one or many diseases, and/or the cellular context (e.g. disease modifiers present and epigenetic milieu) of the cancer(s).
THE BRIEF CASE FOR RARE DISEASE DRUG DEVELOPMENT Distinct regulatory advantages exist for drug development in rare diseases. The 1983 Orphan Drug Act promotes development of new therapies for rare diseases (affecting o200 000 people in the United States 15 ), such as pediatric cancers (for example, RMS). Major advantages include 7 years of FDA-facilitated protection from competition with generic versions of the same drug following marketing approval, waiver of user fees for FDA reviews, as well as tax credits for clinical development costs. 15, 16 More information on the program and grants for clinical studies of Orphan Products is available through the FDA Office of Orphan Products Development (OOPD) website, http://www.fda.gov/ ForIndustry/DevelopingProductsforRareDiseasesConditions/default. htm.
An additional logistical advantage is that approved orphan drugs for cancer typically have had more flexible clinical trial characteristics, including smaller trial size (96 participants for orphan drugs approved vs 290 participants for non-orphan drugs approved in one survey), non-randomized and/or unblended trial design and surrogate end points such as disease response in lieu of survival benefit. 16 Furthermore, the average number of trials per indication can be as low as 1.5 (in one review, 63% of rare cancer indications were based on a single pivotal trial). 17 Parenthetically, smaller clinical trial sizes may make preclinical animal models even more important for prioritization of compounds to move forward to the clinic, particularly physiologically accurate, immunocompetent murine transgenic models 18 or zebrafish models. 11 On the other hand, the potential downside of smaller clinical trial cohort size is that postmarketing trials or safety findings may not confirm the disease advantage of the orphan drug. 16, 19 Nevertheless, overall evaluation of rare cancer trials makes the argument that randomized trial design is both feasible and can demonstrate activity, despite fewer study participants 17 and novel bioinformatics approaches continue to be developed to solve the problem of low statistical power associated with smallsize cohorts. 20, 21 Notable examples exist for proof-of-concept rare diseases that have resulted in accelerated approvals and/or financial advantages for pharmaceutical companies. These examples include Novartis' imatinib for chronic myelogenous leukemia (Novartis, Cambridge, MA, USA), 22 Millennium/Takeda Pharmaceutical's bortezomib for multiple myeloma (Millennium, Cambridge, MA, USA), 23 Novartis' ACZ885 for Muckle-Wells syndrome, 24 Seattle Genetics' brentuximab for Hodgkin's lymphoma and anaplastic large cell lymphoma (Seattle Genetics, Bothell, WA, USA), 25 Pfizer's crizotinib for anaplastic lymphoma kinase-positive advanced nonsmall cell lung cancer (Pfizer, New York City, NY, USA), 25 Merck's vorinostat for cutaneous T-cell lymphoma (Merck, Whitehouse Station, NJ, USA) 26 and Allos Therapeutics' pralatrexate for peripheral T-cell lymphoma (Allos Therapeutics/Spectrum Therapeutics, Henderson, NV, USA). 27, 28 Example of agents initially developed for sarcoma (orphan disease) indications but now being more widely investigated for more common cancer indications includes Zeltia/Johnson & Johnson's agent trabectedin (Zeltia, Madrid, Spain). 29 Importantly, too, rare disease initial FDA indications have in some instances already included pediatric cancer-as in the case of Genzyme's clofarabine for the treatment of relapsed pediatric acute lymphoblastic leukemia (Genzyme, Cambridge, MA, USA). 30 Clofarabine, too, is now being actively investigated for indications in myelodysplasia and hematological malignancies in adults.
THE CASE FOR PEDIATRIC CANCERS AS RARE DISEASES FOR DRUG DEVELOPMENT 2012 AND BEYOND
A culture of childhood cancer cooperative group trials spanning more than four decades lends itself to key features for proof-ofconcept trials. Although only single-digit percentages of adults enroll in National Cancer Institute (NCI)-sponsored clinical trials, 450% of children enroll in such trials. 31 Furthermore, diagnostic biopsies (access to tissue) and predictive biomarkers for patient stratification are not only well characterized but also a major goal of the Children's Oncology Group (COG) overall blueprint for research. 32, 33 Thus, patient enrichment is possible in early-phase proof-of-concept trials for these childhood cancer populations in which response to standard of care is very well established.
From a regulatory point of view, the 2012 FDA Safety and Innovation Act made permanent the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. 34, 35 This legislation encourages more consistent, earlier development of pediatric investigation plans by drug manufacturers. As a result of the 2012 Creating Hope Act, Section 908 of the FDA Safety and Innovation Act includes a (transferrable) Priority Review Voucher system for pharmaceutical sponsors who develop new agents for rare pediatric diseases, thereby reducing FDA review cycle timebut not altering the clinical or scientific criteria of the review process. Additional features include a 6-month extension to patents or FDA exclusivity for marketing rights available in some situations for drugs with pediatric indications. 36 For example, Millennium/Takeda Pharmaceutical has pursued opportunities for primary indications in adult tumors that have orphan drug status but sought exclusivity through pediatric indications (for example, bortezomib for myeloma, but pediatric exclusivity through pediatric leukemia studies; alisertib for peripheral T-cell lymphoma, with pediatric exclusivity also by way of pediatric leukemia studies; in fact, the NCI/PPTP PPTP's preclinical studies screening revealing alisertib (MLN8237) as efficacious in pediatric leukemias was a key factor in promoting pharmaceutical company interest. 37, 38 ). Of note, the Creating Hope Act was authored and championed by the advocacy group Kids-v-Cancer, founded by a parent of a child who lost his life to a pediatric cancer. 39 From a business perspective, too, it seems likely that before cures are developed, new agents will more likely turn pediatric cancers into chronically managed diseases with prolonged disease-free periods. It may be overly optimistic to believe that aggressive pediatric cancers such as RMSs can be turned into chronically managed (but not necessarily disease-free) conditions, as was the case for imatinib in chronic myelogenous leukemia. 22 Certainly in children undergoing continuous physical and intellectual development, a cure without the need for chronic drug administration is preferable. Gore et al very elegantly describe the potential disadvantages to prolonged targeted therapies. 40 Nevertheless, for pediatric patients and their families with incurable conditions like diffuse intrinsic pontine glioma or metastatic sarcomas, the middle ground of prolonged disease-free periods of chronically managed disease might be a readily accepted bridge to the day that preferable, definitive cures are available.
THE CASE FOR RMS DRUG DEVELOPMENT SPECIFICALLY: TARGETS AND SYNERGIES WITH OTHER PROGRAMS
Clinically, survival among metastatic RMS patients has remained unimproved for years, if not several decades. 8, 9 This clinical experience thus far is succinctly summarized in the review by Malempati and Hawkins. 41 On the other hand, the biological understanding of this disease has accelerated over the last decade (Table 1) , with a recent recognition that RMS shares many properties with normal activated muscle stem cells (satellite cells). 11, 12, 96 Therefore, natural synergy could exist between divisions of a pharmaceutical company with both drugdevelopment programs for oncology and muscle disease. Many muscle diseases have significant health-care cost impacts, particularly sarcopenia (age-related muscle wasting) and cancer cachexia-not to mention muscular dystrophy. Ironically, Rare cancers and drug development E Sokolowski et al Rare cancers and drug development E Sokolowski et al muscular dystrophy is also a predisposing factor to RMS in experimental models. [97] [98] [99] [100] As related to epigenetic drug applications (for example, DNA methylation and histonemodifying agents 101 ), the approach of 'myo-differentiation therapy' is plausible, whereby RMS cells are induced to move from an activated stem cell state to a fully differentiated state as rhabdomyoblasts: supportive evidence lies in that nondividing, differentiated (myofiber-like) rhabdomyoblasts have been identified in post-chemotherapy/post-radiation biopsies with relatively little risk of relapse. 102 Epigenetic targets in RMS that may control this differentiation process have recently been reviewed. 103 Furthermore, it is not unreasonable that a pharmaceutical muscle biology section would consider targeting energy flux in hypoxia-favoring RMSs 104 using derivatives of agents such as 2-deoxy-D-glucose, 3-guanidinopropionic acid or metformin.
The expression of the fetal acetylcholine receptor by RMS is an example of a specific opportunity to capitalize on the activated satellite cell phenotype and at the same time co-develop antiidiotype antibodies for the perinatal condition of neonatal myasthenia gravis, a condition whereby maternal anti-acetylcholine receptor antibodies can lead to perinatal hypotonia and respiratory distress. 105, 106 Other RMS-associated cell-surface targets for toxin-conjugated monoclonal antibodies (or immunotherapy 107 ) may also include satellite cell markers such as integrin-b1. 108 Fortunately, too, the potential therapeutic targets in RMS match many of the portfolios of pharmaceutical companies (Table 1) . These potential targets include growth factor receptors (for example, receptor tyrosine kinases and downstream kinases, 73, 75, 109 as well as cytokine receptors (for example, IL-4 receptor 90 ). Transcription of many of these targets in aRMS appear Abbreviations: ALK, anaplastic lymphoma kinase; aRMS, alveolar rhabdomyosarcoma; c-MET, mesenchymal epithelial transition factor; CGH, comparative genomic hybridization; EGFR, epidermal growth factor receptor; eRMS, embryonal rhabdomyosarcoma; FGFR, fibroblast growth factor receptor; FISH, fluorescence in situ hybridization; IGF1R, insulin-like growth factor 1 receptor; IHC, immunohistochemistry; IL-4R, IL-4 receptor; JAK, janus kinase; M-CSFR, macrophage-colony stimulating factor; mTOR, mammalian target of rapamycin; NFkB, nuclear factor-KappaB; PDGFR, platelet-derived growth factor receptor; PRC, protein kinase C; RMS, rhabdomyosarcoma; RT-PCR, reverse transcriptase PCR; SSCP, single-strand conformation polymorphism; STAT, signal transducer and activator of transcription; VEGFR, vascular endothelial growth factor receptor. a With few exceptions, sampling size was very limited for each study. Note also that if a pathway is not listed, that pathway may still be relevant in rhabdomyosarcoma but its prevalence hereunto uninvestigated.
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to be driven by the Pax:Foxo1a fusion gene product (a transcription factor), although in eRMS the expression of the same targets often appear to be activated by alternative mechanisms. 73, 75, 90 The COG Soft Tissue Sarcoma (COG-STS) committee has recently published this cooperative group's blueprint for clinical trial investigation. 7 Although the blueprint is not exclusive of latebreaking agents, COG-STS does point to strong interests in targeted therapies (that is, vascular endothelial growth factor receptor, platelet-derived growth factor receptor, mammalian target of rapamycin and insulin-like growth factor 1, as well as anaplastic lymphoma kinase, mesenchymal epithelial transition factor and fibroblast growth factor receptor 4), which are again in line with drug-development pipelines of many pharmaceutical companies. The COG-STS has several strategies to introduce targeted agents to clinical trials for RMS, which include historic use of Phase II windows in metastatic RMS to prioritize agents, COG Phase I program (COG-DVL) studies to determine pediatric dose with an eye toward Phase II studies and recent strategy to use selection/screening Phase II studies (for example, ARST0921 (ClinicalTrials.gov Identifier NCT01222715)).
Additional opportunities in pediatric cancer orphan product development may lie in high-throughput screens, which are better suited to the industry setting than academics; specifically, one could search for compounds that are synthetic lethal with the unique, pathognomic abnormalities of these rare cancers. 110 For example, Pax3:Foxo1a or Pax7:Foxo1a are found in 70-85% of aRMS.
2 Given that melanoma is frequently associated with splice variant expression of Pax3, 111,112 a natural synergy might exist to explore the commonalities of targeting Pax3:Foxo1a, Pax7:Foxo1a and Pax3 side-by-side. At the same time, these pathognomic genetic abnormalities or their related markers have potential as complementary biomarkers (that is, companion diagnostics) for stratifying patients that will respond to therapy 113 or for following progression of the disease. 114 From a devil's advocate point of view, many of the potential targets listed in Table 1 are based upon reverse transcriptase PCR or immunohistochemistry-expression studies for which underlying genomic amplification or mutations have not (yet) been demonstrated (but may be as DNA deep-sequencing projects come to fruition). DNA-level alterations would more strongly support the role of these biomarkers in tumor maintenance, although experimental evidence that a given potential target is a direct transcriptional target of Pax:Foxo1a 115, 116 is an alternative line of evidence that a target may be worth pursuing. Furthermore, even Pax:Foxo1a may itself be druggable, given new approaches being seen for similar translocation-associated chimeric transcription factors in pediatric Ewing's sarcoma 117 and MLL-associated pediatric leukemias. 118 
THE CASE FOR RMS IN TERMS OF DRUG-DEVELOPMENT RESOURCES
Logistically, a large number of tools are readily available from commercial sources or public repositories for preclinical studies of RMS, including gene-expression and array comparative genomic hybridization data sets, primary tissue, cell lines and genetically engineered animal models. For example, quality genome-wide expression studies of clinical RMS samples are publically available from the Gene Expression Omnibus or by request of the study authors, [119] [120] [121] as well as cross-species data set of zebrafish 11 and mouse RMS models. 12, 122 Human xenograft gene-expression data paired with corresponding cell line data are also available, making possible extraction of tumor microenvironment or 'in vivo' characteristics. 123, 124 In addition, matched normal DNA/RMS DNA deep-sequencing data for 13 patients are available by request via the Pediatric Cancer Genome Project sponsored by St Jude Research Hospital and Washington University, http://explore. pediatriccancergenomeproject.org/ or https://www.ebi.ac.uk/ega/ datasets/EGAD00001000164. A similar project on a larger scale is ongoing by the COG-STS and Javed Khan at the NCI Pediatric Branch. 7 (Note that although the latter is not part of the Therapeutically Applicable Research to Generate Effective Treatments Project, a number of other pediatric cancer genomes have/will be reported from this cooperative group/NCI initiative, http://target.cancer.gov/. 125 ) Primary patient material (including annotated tissue microarrays from RMS and other pediatric cancers 126 ) is available from the COG Biorepository and/or the Pediatric Cooperative Human Tissue Network, whereas the COG Cell Repository also makes available RMS cell lines, http:// www.cogcell.org/. Supplemental Table S1 and Table 2 provide a comprehensive documentation of how to access cell lines, as well as which cell lines contain mutations or activation of pathways of potential interest. The value of transgenic models of pediatric cancer has been reviewed more extensively elsewhere. 18 For a detailed description of eRMS models, see Kikuchi et al. 127 Nevertheless, many of these models (including genetically engineered conditional models) are readily available from the NCI Mouse Models of Human Cancer Consortium (http:// mouse.ncifcrf.gov/) or other repositories such as The Jackson Laboratory. In some cases, these genetically engineered models have been characterized for immunocompetence on a hairless background strain, thereby facilitating preclinical drug studies using optical imaging in the pharma setting. 128 Furthermore, the new Dupont policy removing certain limitations on academicpharma collaboration is a truly enabling step in the use of genetically engineered models. 129 In addition, resources are readily available to facilitate preclinical and clinical trials. The Pediatric Preclinical Testing Program (PPTP) offers a mechanism for testing specific agents. The PPTP panel contains eight RMS human tumor xenograft models, five as primary models (Rh28(aRMS), Rh30(aRMS), Rh30R(relapse tumor from the same Rh30 patient), Rh41(aRMS) and Rh18(eRMS)) and three as secondary models (Rh10(eRMS), Rh36(eRMS) and Rh65(aRMS)). 130 PPTP new agent proposals are first evaluated through the Pediatric Drug Development Group, which includes the NCI Project Officer with pediatric oncology drug-development experience, the Chair of the COG Phase I Consortium and the Principal Investigator of the PPTP. Detailed instructions for submitting a candidate agent can be found at the PPTP website, http://pptp.nchresearch.org/documents/application-process-forpedddg-08-2008.pdf. Furthermore, the European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children with Cancer in Europe are in the process of publishing a RMS model (boilerplate) Pediatric Investigational Plan 131 to speed development of industry-sponsored clinical trials.
From a patient accrual point of view, the contemporary experience of a US pediatric cooperative group for RMS clinical trials incorporating targeted agents was 27 patients/year for firstrelapse disease and 40 patients/year for newly diagnosed, metastatic disease, 7 which are accrual rates making feasible a rare cancer trial. These accrual rates are similar to antecedent COG trials for both cohorts. 7, 132, 133 Inclusion of children at second or later relapse, as well as young adults, would potentially also accelerate accrual.
NEW HORIZONS CAN BE ACHIEVED THROUGH NEW BRIDGES
The role of community involvement also cannot be understated. More so than for other rare diseases, progress in pediatric cancers will increasingly depend on the parents or families who have been affected by these childhood orphan malignancies. Given the small numbers of patients afflicted by any childhood cancer and the ability for a more common adult cancer to mobilize and incentivize pharmaceutical research and development, the motivating drive for action needs to emanate from the collective Rare cancers and drug development E Sokolowski et al [134] [135] [136] The Sarcoma Foundation of America patient registry and biobank is another example of a progressive community resource. 137 For pediatric RMS, European Paediatric Soft Tissue Sarcoma Study Group and COG largely provide an adequate framework-but this should not be exclusive of the community. For example, surprisingly, efforts such as autopsies of pediatric cancer patients for collection of research tissue are often driven at the family and community level 138 (for example, the Northwest Sarcoma Foundation legacy gift transport program 139 ). Although Abbreviations: aRMS, alveolar rhabdomyosarcoma; EGFR, epidermal growth factor receptor; eRMS, embryonal rhabdomyosarcoma; FGFR, fibroblast growth factor receptor; IGF1R, insulin-like growth factor 1 receptor; IL-4R, IL-4 receptor; mTOR, mammalian target of rapamycin; PDGFR, platelet-derived growth factor receptor; PLK, polo-like kinase; PRC, protein kinase C; PTEN, phosphatase and tensin homolog; PI3K, phosphatidylinositol 3-kinase; STAT, signal transducer and activator of transcription; TGF, transforming growth factor; TNFa, tumor necrosis factor; TRAIL, TNF-related apoptosis-inducing ligand; VEGFR, vascular endothelial growth factor receptor. Note: Many agents targeting these pathways have been tested by the PPTP and found not to have in vivo activity for the rhabdomyosarcoma cell lines tested. These results may not preclude that in cell lines not tested or in selected rhabdomyosarcoma patient populations that activity might be found. Also, candidate targets in this table may not be in Table 1 for lack of clinical sample biomarker prevalence studies.
Rare cancers and drug development E Sokolowski et al long recognized of value to the medical community historically and contemporarily, 140 autopsies for research seem to gain much more traction when promoted and requested by parents, seeking answers to why therapy may have failed their child, and hoping that knowledge gained by a selfless postmortem donation of tissue might prevent the death of child like their own in the future. 138 From a scientific perspective, the major logistical problem to research and development is the scarcity of tissue from the patients whom standard of care has failed and where relapsed surgical biopsies are unavailable; autopsies for research offer the greatest opportunity to gain insight into the driving of biological factors underlying disease progression and treatment failure. The community can also raise awareness of clinical trial opportunities, a role that occurs almost by default through patient and family listservs such as the Association of Cancer Online Resources, www.acor.org. The role of the community in legislative advocacy was mentioned earlier in this review. Importantly, too, funding from community advocacy groups can in some cases be more flexible, more timely and less administratively burdened than government sources when trying to build academic-pharma bridges (whether through private investment in the academic or the pharma side). An example of this is the venture philanthropy role of Accelerate Brain Cancer Cures Foundation in annually bringing together academic, pharmaceutical and community stakeholders with the promise of seed funds to empower new relationships-such as the investment that occurred when bevacizumab was first contemplated for glioblastoma multiforme. Thus, community groups and foundations create an important, if not essential, landscape for pediatric cancers to reach their fullest potential as proof-of-concept diseases.
Lastly, it would be important to emphasize the inclusion of industry stakeholders at every level of discovery, preclinical and clinical studies in the nonprofit sectors (acknowledging that industry participation in some cooperative group clinical trial discussion may be precluded). Not unexpectedly, pediatric oncologist (and non-oncologist) internal champions can be found within multiple divisions of the pharmaceutical industry, whose company-wide cultures and mantras are congruent with addressing the improved outcome and quality-of-life of pediatric cancer patients. Near-term, tangible actions by these internal champions might include incorporation of pediatric cancer cell lines into the drug-development screening panels, as well as the earliest possible initiation of pediatric investigation plans, if not also feedback to the FDA and other regulatory agencies to extend the pediatric exclusivity incentive from 6 months to 1-2 years.
SUMMARY
Although childhood cancers including RMS are rare compared with some tumors of adulthood, pediatric cancers by in large display common genetic abnormalities (for example, PAX3:-FOXO1A) that are critical drivers of malignancy. These pathognomic mutations may elicit more consistent and homogeneous tumor biology when compared with adult cancers; thus, pediatric cancers may be easier to target with emerging non-chemotherapy drugs. Whether in the context of traditional biomarker-stratified clinical trials or novel designs for personalized cancer therapy, the outlook for public-private partnerships in RMS drug development looks bright-either by turning these conditions into chronically managed conditions with prolonged disease-free periods or (preferably) through definitive cures.
CONFLICT OF INTEREST
CK has received single-time honoraria for scientific presentations at Novartis, Millennium/Takeda Pharmaceutical and GlaxoSmithKline, and has research joint ventures or sponsored research with Novartis and Johnson & Johnson. CK is also a paid consultant to the NCI/CTEP Pediatric Preclinical Testing Program (PPTP). The remaining authors declare no conflict of interest.
